アルツハイマー病の再考:新しいmiRNAsは,脳を超えた病気を明るくする
J S Novotný1,2, M Čarná1, E B Dammer3
1Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic.
Molecular psychiatry
|February 13, 2026
まとめ
アルツハイマー病 (AD) は,新型を含む循環するマイクロRNA (miRNA) の広範な変化を伴う. これらの発見は,ADは脳特異性だけでなく,全身的な障害である可能性を示唆し,バイオマーカーと治療法のための新しい道を開く.
科学分野:
- 神経科学は神経科学である.
- 遺伝学 遺伝学とは
- バイオケミストリー バイオケミストリー
背景:
- アルツハイマー病 (AD) は世界的に大きな課題となっているが,その病原性は未だに十分に理解されていない.
- 新興の証拠は,AD患者の循環中のマイクロRNA (miRNA) の複雑な変化を示しています.
研究 の 目的:
- メタ解析を用いてアルツハイマー病に関連するmiRNAの変化を包括的に特徴づける.
- ADの病原化に関与する新しいmiRNAと生物学的経路を特定する.
主な方法:
- 4186人の参加者を含む22の研究から得られたデータについて,2つのメタアナリティカルアプローチを実施しました.
- 2895のミクロRNAの包括的なセットを特定し,ADの有意な変化を有するものを分析しました.
主要な成果:
- ADの広範な変化を有する194のミクロRNAが特定され,以前は病気と関連付けられていない32の新しいミクロRNAが含まれています.
- miRNA標的の分析により,インタールイキンシグナル伝達,トール受容体シグナル伝達,p38 MAPK,およびインスリン/IGF経路を含む,十分に理解されていない生物学的経路が明らかになった.
- いくつかの特定された"AD miRNAs"が脳の外部で発見され,システミックな役割を示唆しました.
結論:
- アルツハイマー病は,独占的に脳特異的ではなく,全身的な障害である可能性があります.
- 発見は,ADの病原性におけるmiRNAの関与の理解を広げ,潜在的な全身的経路を強調しています.
- 結果は,新しいADバイオマーカーおよびmiRNA標的治療の開発のための基盤を提供します.
さらに関連する動画
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
09:47DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
Published on: December 15, 2023
関連する概念動画
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...